US3928552A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Hepato-biliary radiopharmaceutical comprising 2-mercaptoisobutyric acid chelating reduced technetium-99m
Assignee: United States Department of Energy
•
Filing: 1973-10-18
•
Granted: 1975-12-23
•
Expires: 1993-10-18
Abstract
Abstract A radiopharmaceutical comprising 2-mercaptoisobutyric acid chelating reduced technetium-99m for scintigraphically imaging the liver and biliary tract morphology and function and to a method for instantly making the radiopharmaceutical.
Inventors
- 👤 Harry S Winchell
- 👤 Archie S Khentigan
- 👤 Hong Lin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 20:31
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/0474; A61K51/0478; A61K2123/00
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
13 words
A RADIOPHARMACEUTICAL FOR SCINTIGRAPHIC ORGAN IMAGING COMPRISING 2-MERCAPTOISOBUTYRIC ACID LABELED WITH REDUCED TECHNETIUM-99M.
Claim 2
Dependent Claim
13 words
A RADIOPHARMACEUTICAL FOR SCINTIGRAPHIC ORGAN IMAGING COMPRISING 2-MERCAPTOISOBUTYRIC ACID LABELED WITH REDUCED TECHNETIUM-99M.
Claim 3
Dependent Claim
28 words
The radiopharmaceutical of claim 1 wherein the 2-mercaptoisobutyric acid is in aqueous solution and the technetium-99m is maintained in the reduced state by the presence of stannous tin.
Claim 4
Dependent Claim
19 words
A radiopharmaceutical consisting of mixed aqueous solutions of 2-mercaptoisobutyric acid and stannous chloride; and technetium-99m pertechnetate in physiological saline.
Claim 5
Dependent Claim
19 words
A radiopharmaceutical consisting of mixed aqueous solutions of 2-mercaptoisobutyric acid and stannous chloride; and technetium-99m pertechnetate in physiological saline.
Claim 6
Dependent Claim
20 words
The radiopharmaceutical of claim 3 wherein the molar proportion of the 2-mercaptoisobutyric acid to stannous chloride is 3 to 1.
Claim 7
Independent Claim
40 words
The method of making an instantly labeled liver specific radiopharmaceutical comprising the steps of preparing a reagent of mixed aqueous solutions of 2-mercaptoisobutyric acid and stannous chloride; and then adding to said reagent technetium-99m pertechnetate ions in physiological saline solution.
Claim 8
Independent Claim
40 words
The method of making an instantly labeled liver specific radiopharmaceutical comprising the steps of preparing a reagent of mixed aqueous solutions of 2-mercaptoisobutyric acid and stannous chloride; and then adding to said reagent technetium-99m pertechnetate ions in physiological saline solution.
Claim 9
Independent Claim
68 words
The method of serially imaging the liver and biliary tract of a patient comprising the steps of preparing a radiopharmaceutical from 2-mercaptoisobutyric acid and technetium-99m maintained in the reduced state by the presence of stannous tin; intravenously injecting the patient with said radiopharmaceutical; and then scintigraphically imaging the liver and biliary tract to follow movement of radioactivity into the liver and then from it through the biliary tract.
Claim 10
Independent Claim
68 words
The method of serially imaging the liver and biliary tract of a patient comprising the steps of preparing a radiopharmaceutical from 2-mercaptoisobutyric acid and technetium-99m maintained in the reduced state by the presence of stannous tin; intravenously injecting the patient with said radiopharmaceutical; and then scintigraphically imaging the liver and biliary tract to follow movement of radioactivity into the liver and then from it through the biliary tract.
Claim 11
Independent Claim
37 words
The method of imaging localized pathologic lesions in a patient comprising the steps of preparing a radiopharmaceutical from 2-mercaptoisobutyric acid labeled with reduced technetium-99m; intravenously injecting the patient with said radiopharmaceutical; and then scintigraphically imaging the lesion.
Claim 12
Independent Claim
37 words
The method of imaging localized pathologic lesions in a patient comprising the steps of preparing a radiopharmaceutical from 2-mercaptoisobutyric acid labeled with reduced technetium-99m; intravenously injecting the patient with said radiopharmaceutical; and then scintigraphically imaging the lesion.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1978-12-22 | 1979-06-23 | 1979-12-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1982-12-22 | 1983-06-23 | 1983-12-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1986-12-22 | 1987-06-23 | 1987-12-23 | $7700.00 | Window Closed / Lapsed |